Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | PKM | P14618 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.48 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8147273 | 0.85 | MAPT (0.65) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL8744502 | 0.85 | MAPT (0.58) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL4557828 | 0.83 | KAT2B (0.64) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL14364287 | 0.83 | MAPT (0.60) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL16152114 | 0.83 | HCAR3 (0.66) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL10428098 | 0.83 | HCAR3 (0.66) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL17923845 | 0.83 | KAT2B (0.64) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL30413993 | 0.83 | KAT2B (0.64) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL20968369 | 0.83 | HCAR3 (0.66) | MAPTPOLBPKMKDM4EALDH1A1 | |
| SCHEMBL2228171 | 0.83 | KAT2B (0.64) | MAPTPOLBPKMKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | NIH - DEITR | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099800-A1 | NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF | PNLIP, LIPE, LIPC | MAPT 4568/4885POLB 4226/4885PKM 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.